Jiang et al. [53,54], investigating genomic profiles of patients diagnosed with stage I primary NSCLC, found some aberrations (including SP-A deletion), possibly associated with tumorigenesis and potentially useful as disease markers. Here, SFTPA2 is linked to non-small cell lung carcinoma.